News
NAFC Encourages SCI and MS Patients to Participate in Research
The National Association For Continence (NAFC) seeks to connect consumers in a phase III international multi-center clinical trial, the Dignity Study.
July 31, 2008 (CHARLESTON, SC) – The Dignity Study will determine the effectiveness and safety of an investigational minimally invasive procedure for controlling symptoms of overactive bladder (OAB) in patients with spinal cord injury or multiple sclerosis (MS). Allergan, Inc., one of NAFC’s Industry Council members, is conducting this research.
Individuals with a spinal cord injury or MS often develop a neurogenic bladder, which is loss of bladder control caused by damage to part of the nervous system. This neurogenic bladder causes OAB, or symptoms of frequency and urgency that may include urge incontinence. Allergan, Inc. has developed a treatment that is being tested for its ability to cure or manage urinary incontinence that occurs in people with OAB specifically caused by spinal cord injury or MS. In a previous medical research study conducted by Allergan, the investigational procedure involving an injection into the bladder reduced the frequency of urinary incontinence in subjects being studied. The material injected and under study is Botulinum toxin type A.
Qualified participants will have had a spinal cord injury or have been clinically diagnosed with MS and experience incontinence due to an overactive bladder. Potential participants will be evaluated to further determine their eligibility based on additional screening criteria. For participants, the investigational study injections, medical exams, and lab tests will be provided at no charge. Interested parties should visit www.dignitystudy.com or call 1.888.61.STUDY (1.888.617.8839) to complete a questionnaire to determine if you might qualify to participate.
This announcement and information about other clinical trial research related to the diagnosis and treatment of bladder and bowel control problems, voiding dysfunction including retention, noctural enuresis, and related pelvic floor dysfunction are now incorporated in NAFC’s Web site. For more information about this study and other clinical research available, visit the Clinical Trial page in the Bladder and Bowel Health section of the NAFC Web site, www.nafc.org/bladder-bowel-health/finding-help or call 1.800.BLADDER .
Individuals with a spinal cord injury or MS often develop a neurogenic bladder, which is loss of bladder control caused by damage to part of the nervous system. This neurogenic bladder causes OAB, or symptoms of frequency and urgency that may include urge incontinence. Allergan, Inc. has developed a treatment that is being tested for its ability to cure or manage urinary incontinence that occurs in people with OAB specifically caused by spinal cord injury or MS. In a previous medical research study conducted by Allergan, the investigational procedure involving an injection into the bladder reduced the frequency of urinary incontinence in subjects being studied. The material injected and under study is Botulinum toxin type A.
Qualified participants will have had a spinal cord injury or have been clinically diagnosed with MS and experience incontinence due to an overactive bladder. Potential participants will be evaluated to further determine their eligibility based on additional screening criteria. For participants, the investigational study injections, medical exams, and lab tests will be provided at no charge. Interested parties should visit www.dignitystudy.com or call 1.888.61.STUDY (1.888.617.8839) to complete a questionnaire to determine if you might qualify to participate.
This announcement and information about other clinical trial research related to the diagnosis and treatment of bladder and bowel control problems, voiding dysfunction including retention, noctural enuresis, and related pelvic floor dysfunction are now incorporated in NAFC’s Web site. For more information about this study and other clinical research available, visit the Clinical Trial page in the Bladder and Bowel Health section of the NAFC Web site, www.nafc.org/bladder-bowel-health/finding-help or call 1.800.BLADDER .
